We are live on ! Find out more
ICPT

Intercept Pharmaceuticals, Inc.

Delisted

ICPT was delisted on the 7th of November, 2023.

191 hedge funds and large institutions have $4.36B invested in Intercept Pharmaceuticals, Inc. in 2015 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 95 increasing their positions, 47 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

102% more repeat investments, than reductions

Existing positions increased: 95 | Existing positions reduced: 47

5% less funds holding

Funds holding: 200191 (-9)

13% less capital invested

Capital invested by funds: $5.01B → $4.36B (-$646M)

15% less call options, than puts

Call options by funds: $115M | Put options by funds: $136M

21% less first-time investments, than exits

New positions opened: 27 | Existing positions closed: 34

33% less funds holding in top 10

Funds holding in top 10: 32 (-1)

Holders
191
Holders Change
-9
Holders Change %
-4.5%
% of All Funds
5.15%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.05%
New
27
Increased
95
Reduced
47
Closed
34
Calls
$115M
Puts
$136M
Net Calls
-$20.2M
Net Calls Change
-$51.9M
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$872M +$7.39M +27,760 +0.8%
Ameriprise
2
Ameriprise
Minnesota
$361M +$179M +672,471 +82%
CG
3
Carmignac Gestion
France
$320M -$6.6M -24,780 -2%
O
4
OrbiMed
New York
$270M
Vanguard Group
5
Vanguard Group
Pennsylvania
$242M +$12.4M +46,640 +5%
Capital World Investors
6
Capital World Investors
California
$188M
FAM
7
Fred Alger Management
New York
$124M +$8.08M +30,330 +6%
First Trust Advisors
8
First Trust Advisors
Illinois
$118M -$40.2M -150,815 -24%
BFA
9
BlackRock Fund Advisors
California
$109M +$15.1M +56,691 +14%
BIT
10
BlackRock Institutional Trust
California
$83.5M +$4.58M +17,192 +5%
Jennison Associates
11
Jennison Associates
New York
$83.4M -$32M -120,096 -26%
T. Rowe Price Associates
12
T. Rowe Price Associates
Maryland
$79.2M -$20.4M -76,784 -19%
JP Morgan Chase
13
JP Morgan Chase
New York
$70.4M +$4.56M +17,108 +6%
Franklin Resources
14
Franklin Resources
California
$66.6M
CWAM
15
Columbia Wanger Asset Management
Illinois
$66.5M -$10.7M -40,171 -13%
State Street
16
State Street
Massachusetts
$64.9M +$10.7M +40,288 +18%
CCI
17
Columbus Circle Investors
$54.4M +$24.1M +90,554 +67%
Credit Agricole
18
Credit Agricole
France
$54.2M +$13.7M +51,550 +30%
AGA
19
Altrinsic Global Advisors
Connecticut
$46M -$12.8M -48,090 -20%
BB
20
BB Biotech
Switzerland
$43.6M +$6.85M +25,719 +17%
Wells Fargo
21
Wells Fargo
California
$43.3M +$43.2M +162,208 +926%
SAM
22
Sectoral Asset Management
Quebec, Canada
$42.9M +$3.38M +12,700 +8%
Deutsche Bank
23
Deutsche Bank
Germany
$42.6M +$11.4M +42,870 +32%
MAA
24
Managed Account Advisors
New Jersey
$42.1M +$21M +78,689 +82%
AWG
25
Alpha Wave Global
New York
$39.5M -$29.6M -111,300 -40%

ICPT Hedge Fund Activity: Q2 2015 in Review

191 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q2 2015, worth a combined $4.36B — down 13% from $5.01B a quarter earlier.

Sellers outnumbered buyers: 34 funds closed out of ICPT and 27 opened new positions — a net loss of 7 holders — while 47 trimmed existing stakes and 95 added.

The largest buyer was Ameriprise, adding an estimated $179M. The largest seller was Millennium Management, cutting an estimated $87.5M.

  • 191 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q2 2015, down from 200 in Q1 2015.
  • Funds reported $4.36B of Intercept Pharmaceuticals, Inc. stock for Q2 2015, down 13% quarter-over-quarter.
  • 27 funds opened new Intercept Pharmaceuticals, Inc. positions in Q2 2015 and 34 closed out, a net change of -7 holders.
  • The largest Intercept Pharmaceuticals, Inc. buyer in Q2 2015 was Ameriprise, an estimated $179M added.
  • The largest Intercept Pharmaceuticals, Inc. seller in Q2 2015 was Millennium Management, an estimated $87.5M sold.

Based on aggregated 13F filings for Q2 2015.